---
schema_version: "secwatch.filing_event.v1"
accession: "0001635088-26-000060"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-05-20T11:14:10+00:00"
generated_at: "2026-05-20T11:15:28.044653+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant reports Q4 GAAP EPS $0.28 on Moderna settlement; IMVT-1402 D2T RA ACR20 72.7%

## Summary
- Q4 GAAP income from continuing ops $355.7M ($0.28 diluted EPS) vs loss of $252.4M ($0.29 loss) YoY; includes $770M gain on Moderna settlement.
- Non-GAAP loss from continuing ops $222.7M in Q4 vs $154.4M loss YoY; FY loss $747.7M vs $623.9M.
- IMVT-1402 in D2T RA: Week 16 ACR20 72.7%, ACR50 54.5%, ACR70 35.8% in open-label period; 170 patients enrolled.
- Brepocitinib NDA for DM accepted with Priority Review; launch by end Sep 2026. Breakthrough Therapy for cutaneous sarcoidosis.
- Moderna settlement: $2.25B global; $950M due July 2026; additional $1.3B contingent on appeal resolution.

## SEC filing metadata
- accession: 0001635088-26-000060
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-05-20T11:14:10+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/0001635088-26-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/roiv-20260520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001635088-26-000060
- JSON: https://secwatch.observer/filing/0001635088-26-000060.json
- Plain text: https://secwatch.observer/filing/0001635088-26-000060.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2026.
  - Period: fourth quarter and fiscal year ended March 31, 2026
  - Result: reported results
  source text: On May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/0001635088-26-000060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.